A Registry Study of Biomarkers in Ischemic Heart Disease ( BIOMS-IHD )

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05965882

Enrollment

5000

Registered

2023-07-28

Start date

2016-06-30

Completion date

2024-06-30

Last updated

2024-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

Ischemic heart disease

Brief summary

The registry study aims to discover biomarkers for accurate classification and risk assessment of ischemic heart disease.

Detailed description

The purpose of this study is to discover biomarkers for early identification, diagnosis, molecular classification, and intervention based on the mechanism of ischemic heart disease（IHD）. Using mass spectrometry-based metabolomics and multimodal imaging technology, the study aims to further construct a new system for early risk stratification of IHD based on abnormal metabolites.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

: * Aged 18 years or older. * Previous ischemic symptoms/signs or electrocardiographic ischemic changes and. * \>70% stenosis of at least one epicardial coronary artery on angiography or a history of myocardial infarction or coronary revascularization.

Exclusion criteria

* Current known inability to follow instructions or comply with follow-up procedures. * Eligible patients without informed consent form

Design outcomes

Primary

Measure	Time frame	Description
Number of hospitalizations for acute heart failure (HF)	These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge	Unplanned emergency visits or hospitalizations leading to HF deterioration were defined as hospitalizations for HF

Secondary

Measure	Time frame	Description
Number of major adverse cardiovascular events (MACE)	These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge	Major adverse cardiovascular events (MACE) in overall population, defined as composite of all-cause death, Heart Failure hospitalization, recurrent myocardial infarction, stroke or ischemia-driven revascularization.

Countries

China

Contacts

Primary ContactYuan Wang, PhD

wangyuan980510@163.com13910161443

Backup ContactYangkai Fan, PhD

fan@mail.ccmu.edu.cn15010188587

Outcome results